COVID-19 Outcomes in Patients With Cancer: Miao Liu, MD, PhD

Patients with cancer face unique challenges in the midst of the COVID-19 pandemic: not only do they have an increased risk of contracting COVID-19 in hospital settings, but they also experience more severe clinical outcomes from the disease compared with patients without cancer. In this interview with i3 Health, Miao Liu, MD, PhD, one of the investigators who recently reported these findings in Cancer Discovery, discusses the difficult challenges that patients with cancer face as they continue t...
Continue reading

Sacituzumab Govitecan for TNBC: An Interview With Sara Tolaney, MD, MPH

The FDA recently granted approval to sacituzumab govitecan-hziy (Trodelvy™, Immunomedics, Inc) for patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies. Approval was based on a clinical trial (NCT01631552) that enrolled 108 patients with metastatic TNBC. In an interview with i3 Health, Sara Tolaney, MD, MPH, one of the study authors, provides insights on treating TNBC and the significance of the sacituzumab govitecan approval. What are the ...
Continue reading

Oncology Practice and COVID-19: Addressing the Challenges With Mark A. Lewis, MD

The COVID-19 pandemic has created multiple challenges to cancer care, ranging from the risk of exposure to novel coronavirus involved in having patients come to the hospital or clinic for treatment to the risks that immunosuppressive cancer treatments––and cancer itself––may pose in making patients more susceptible to COVID-19. How should these risks be balanced against the necessity of life-preserving cancer therapies? Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain He...
Continue reading

Encorafenib/Cetuximab for BRAF V600E–Mutant Metastatic Colorectal Cancer: Scott Kopetz, MD, PhD, FACP

After patients with metastatic colorectal cancer who have a BRAF V600E mutation stop responding to first-line treatment, they have a median survival of only four to six months. These patients now have a new option in a combination therapy consisting of encorafenib (Braftovi®, Array BioPharma) and cetuximab (Erbitux®, Lilly), which was approved by the FDA earlier this month for adults with previously treated BRAF V600E-mutated metastatic colorectal cancer. In this interview with i3 Health, Scott ...
Continue reading

Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Upper-tract urothelial cancer (UTUC) is a rare cancer that often needs to be treated with radical surgery, typically entailing complete removal of the affected kidney, ureter, and bladder cuff. Mitomycin C formulated with a reverse thermal hydrogel (JelmytoTM, UroGen Pharma), recently approved by the FDA as the first agent specifically indicated for the treatment of low-grade UTUC, will now allow some patients to keep a kidney that would otherwise have needed to be removed. In this interview wit...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.